返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® NeuroTech Donates WILLIS® to an Injured in Jiuzhaigou Earthquake

[2017-10-26] 

Mianyang, China – MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") recently donated a WILLIS® Intracranial Stent Graft System ("WILLIS®") to a patient injured in the Jiuzhaigou earthquake, which helped save his life with the professional treatment of the medical team of Mianyang Central Hospital and West China Hospital of Sichuan University.
 
At 9:19 pm on August 8, 2017, a magnitude 7.0 earthquake struck a remote, mountainous part in Jiuzhaigou County, Sichuan Province, with the epicenter monitored at 33.2 degrees north, 103.82 degrees east. After the earthquake, Mianyang Central Hospital rapidly organized relief work and rescue 47 injured. One of the injured is a 36-year-old male who suffered from Intracranial vascular rupture caused by trauma. After group consultation of Director Qiyu Liu of Mianyang Central Hospital and his team under the direction of Professor Xiaodong Xie of West China Hospital of Sichuan University, the experts chose to use WILLIS® for endovascular graft exclusion of internal carotid.
 
After learning the situation from Director Qiyu Liu, MicroPort® NeuroTech decided to donate a WILLIS® to the patient. The operation was performed by Professr Xiaodong Xie and the medical team of Mianyang Central Hospital. After the operation, the patient’s intracranial vascular was repaired and he was discharged with a good prognosis after receiving perioperative treatment and care.
 
Researched and developed independently by MicroPort® NeuroTech, WILLIS® gained approval from China Food and Drug Administration ("CFDA") in 2013. It is the first stent graft system indicated for the treatment of intracranial aneurysms that has gained market approval in China. It is also the first medical device to achieve complete vascular reconstruction in China. WILLIS® is also easy to operate. In the above-mentioned case, WILLIS® achieves excellent treatment efficacy by immediate occlusion of the injured blood vessel.
 
As a company with a strong sense of social responsibility, MicroPort® NeuroTech often participates in donation activities to give back to the society. MicroPort® NeuroTech hopes to work together with more experts who are also enthusiastic about public welfare to provide better medical devices and service to patients, bringing them hope of new life.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Hosts Training Course of Medical Device Inspector Training Base
[Next]:MicroPort® EP Attends 2017 Guangdong Medical Association Cardiology Academic Annual Meeting to Display Columbus™